Nabil Ismaili

Medical Oncologist

After five years of medical school at Mohammed V University, Faculty of Medicine and Pharmacy and two years of medical practice at the University Hospital in Rabat - Morocco, Dr. Nabil Ismaili joined the department of medical oncology at the National Institute of Oncology in Rabat where he spent four years and the department of medical oncology at Léon-Bérard Cancer Center in France for a one year spell. The main research areas in which he participated concerned different types and aspects of cancer diseases: breast cancers, urological cancers, and nasopharyngeal cancers. Dr. Ismaili published several scientific papers dealing with concurrent chemoradiotherapy in cancer of the breast, bladder cancer and nasopharyngeal cancer. He is an executive member in various associations in Cancer Research (MEACR: Middle East Association of Cancer Research; ASCAS: Association Scientifique des Cancérologues du Sud). In addition, he has several certificates in different fields of oncology (short trainings in Morocco and abroad). Dr. Ismaili is presently with the Regional Cancer Center of Agadir in Morocco where he serves as a medical oncologist.

1books edited

Latest work with IntechOpen by Nabil Ismaili

Gastric cancer is the fifth most common cancer and the second most common cause of cancer death worldwide. More than 50% of the patients have advanced disease at diagnosis and in this case the disease has a poor outcome. The staging of gastric cancers is based on endoscopic ultrasound, computed tomography, magnetic resonance imaging, positron emission tomography, in addition to the laparoscopic staging. Many improvements in the surgical techniques have been seen in the last decade. Laparoscopic surgery is an emerging approach which offers important advantages: less blood loss, reduced postoperative pain, accelerated recovery, early return to normal bowel function and reduced hospital stay. D1 lymphadenectomy, with a goal of examining 15 or greater lymph nodes is a standard. D2 dissection is considered as a standard in several institutions especially in eastern Asia. Perioperative chemotherapy and adjuvant concurrent radiochemotherapy are recognized as standards treatments. Palliative chemotherapy is the mainstay treatment of advanced stages of the disease (metastatic and non-operable tumors). Despite these treatment advances, the prognosis of gastric cancer remains poor with a 5-year survival ranging from 10 to 15% in all stages combined.

Go to the book